Researchers at the University of Jyväskylä (Finland), in cooperation with national and international research groups, have ...
Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...
The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.
A recent international research project has used advanced microscopy techniques and computational modeling to discover why ...
Current treatments for herpes simplex virus 1 (HSV-1) mainly target the viral DNA polymerase, but resistance is becoming an increasing problem. By understanding how HSV-1 initiates replication, ...
All organisms — from fungi to mammals — have the capacity to evolve and adapt to their environments. But viruses are master shapeshifters with an ability to mutate greater than any other organism. As ...